ClinicalTrials.gg
Not yet recruitingNCT07664943Updated Jun 24, 2026

The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence

An interventional study of Eye drop cap monitor in Glaucoma and Medication Adherence, sponsored by Universal Adherence LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Universal Adherence LLC · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Most patients with glaucoma use eye drops to lower their intraocular pressure. However, poor adherence to prescribed eye drop regimens can lead to significant loss of vision-related quality of life. This study will test the iDrop Device (iD2), a device-on-cap electronic platform monitor designed to accurately track when a research participant removes an eye drop bottle cap, wirelessly communicate usage data to a database accessible to researchers, and send on-demand alerts when a medication is due. A device capable of tracking eye drop usage and sending dosage alerts will test the hypothesis that electronic reminders improve medication adherence and help research subjects improve their eye drop taking behavior. While our primary focus is on glaucoma adherence, this device could also benefit those with other chronic eye conditions requiring regular eye drop treatment, such as dry eye, corneal endothelial disease, eye infections, and uveitis.

02

Conditions studied

  • Glaucoma
  • Medication Adherence

Keywords

  • iD2
  • Adherence
  • Medication
  • Glaucoma
  • Device
03

In context

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.

This study's planned enrollment of 100 is above the median of 61 across 964 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Universal Adherence LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Taking at least one glaucoma drop daily
  • A history of poor adherence when taking glaucoma eye drops. This is determined as an answer of 80% or less for the following question: "Over the past month, what percentage of your drops do you think you took correctly?"
  • Owns a functioning smart phone with Bluetooth and cellular connectivity

Exclusion criteria

Exclusion Criteria:

  • Advanced cognitive impairment
  • Current or expected pregnancy during the study.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Reminders during Stage 2 of study

    Stage 2 of the study is a 45-day period with 1:1 random assignment to determine the effect of no reminders vs. smart cap reminders if the drop is not used within the designated time window. This arm will receive smart cap reminders.

    Device: Eye drop cap monitor

  • No intervention
    No reminders during Stage 2 of study

    Stage 2 of the study is a 45-day period with 1:1 random assignment to determine the effect of no reminders vs. smart cap reminders if the drop is not used within the designated time window. This arm will not receive smart cap reminders.

Interventions

  • DeviceEye drop cap monitor

    Eye drop cap monitor for improving adherence

    Also known as: iD2, iDrop Device

06

What researchers measure

Primary outcomes

  1. Change in Adherence when Using the Dose Monitor

    The iD2 device will track when the bottle cap is removed as a measure of medication adherence. Adherence will be measured throughout the study, comparing adherence when dose reminders are given against when no dose reminders are given.

    Time frame: 150 days

Secondary outcomes

  1. Participant Satisfaction with the Dose Monitor

    A participant's satisfaction with the dose monitor is measured using a questionnaire administered during the last study visit. 8 questions will use a 1-5 Likert scale, with 1 corresponding to "Strongly Disagree" and 5 corresponding to "Strongly Agree" in response to statements regarding device satisfaction, such as "I would use this device again." 7 questions are open-ended.

    Time frame: 150 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07664943
Lead sponsor
Universal Adherence LLC
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Steven Mansberger, MD, MPH
Contact
clinicaltrials@deverseye.org
503-413-8495
Steven Mansberger, MD, MPH
principal investigator · U n i v e r s a l A d h e r e n c e , L L C
Robert Kinast, MD
principal investigator · U n i v e r s a l A d h e r e n c e , L L C
Brian Breiling, MS, BS
principal investigator · U n i v e r s a l A d h e r e n c e , L L C
Vince O'Malley
principal investigator · U n i v e r s a l A d h e r e n c e , L L C

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion